The Xenograft Core for NF1 Experimental Therapeutics is designed to provide timely and cost-efficient access to animal models of neurofibromatosis-related cancers using human tumor derived cells. We have successfully established human xenograft models of malignant peripheral nerve sheath tumors (MPNSTs) in athymic nude mice. While xenograft models in general are considered to be less authentic relative to human disease then native, spontaneous tumor models, they have the advantage of being rapid, measurable and predictable. Another important advantage for some types of biologic therapeutic applications is that xenograft tumors are of human origin, and are therefore more appropriate for the study of agents directed at therapeutic targets that may differ in human and mouse cells (such as antibodies or gene-based therapies using human viruses). The Xenograft Core gives Cincinnati Center for Neurofibromatosis Research members access to expertise and services they would otherwise need to individually acquire, providing an economy of effort. Services include maintenance and quality control of human cell lines, mouse injections for tumor formation, drug administration, animal monitoring and serial measurements of tumor growth, serial blood sampling for pharmacokinetic studies, necropsy and harvesting of tumor and organs for microscopic evaluation and pharmacodynamic (target validation) studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS057531-02
Application #
7911617
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2009-07-01
Budget End
2010-06-30
Support Year
2
Fiscal Year
2009
Total Cost
$92,714
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
Wu, Jianqiang; Keng, Vincent W; Patmore, Deanna M et al. (2016) Insertional Mutagenesis Identifies a STAT3/Arid1b/?-catenin Pathway Driving Neurofibroma Initiation. Cell Rep 14:1979-90
Jousma, Edwin; Rizvi, Tilat A; Wu, Jianqiang et al. (2015) Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1. Pediatr Blood Cancer 62:1709-16
Haworth, Kellie B; Leddon, Jennifer L; Chen, Chun-Yu et al. (2015) Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr Blood Cancer 62:571-6
Wu, J; Patmore, D M; Jousma, E et al. (2014) EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene 33:173-80
Watson, Adrienne L; Anderson, Leah K; Greeley, Andrew D et al. (2014) Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Oncotarget 5:1502-14
Moriarity, Branden S; Rahrmann, Eric P; Beckmann, Dominic A et al. (2014) Simple and efficient methods for enrichment and isolation of endonuclease modified cells. PLoS One 9:e96114
Brundage, M E; Tandon, P; Eaves, D W et al. (2014) MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. Oncogene 33:5626-36
Rahrmann, Eric P; Watson, Adrienne L; Keng, Vincent W et al. (2013) Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet 45:756-66
Prada, Carlos E; Jousma, Edwin; Rizvi, Tilat A et al. (2013) Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol 125:159-68

Showing the most recent 10 out of 21 publications